Skip to main content
Log in

Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The efficacy of low-dose radioiodine therapy (RIT) for intermediate-risk or high-risk differentiated thyroid cancer (DTC) patients is controversial. Because of the country's shortage of medical facilities for RIT, 1110-MBq RIT for higher risk DTC patients has been performed on an outpatient basis since 2010 in Japan. Herein, we addressed this issue and attempted to determine prognostic factors for the prediction of RIT outcomes.

Methods

We retrospectively analyzed the cases of 119 patients with papillary thyroid cancer who underwent their first RIT with 1110 MBq radioactive iodine (RAI) following a total thyroidectomy, including 65 (54.6%) intermediate-risk and 54 (45.4%) high-risk patients (according to Japan's 2018 clinical practical guidelines for thyroid tumors). Successful ablation was defined when a negative I-131 whole-body scan and thyroglobulin (Tg) < 2 ng/mL were obtained at a diagnostic scan performed 148–560 days (median 261 days) after the first RIT.

Results

The overall ablation success rate was 23.4%. Although the ablation success rates of each pretreatment protocol [recombinant human thyroid stimulating hormone and thyroid hormone withdrawal (THW)] did not differ significantly, THW tended to result in a higher success rate than rhTSH. The Tg level at RIT was the only independent powerful predictive factor for successful ablation. The best cut-off value of Tg for predicting unsuccessful ablation was 9 ng/mL.

Conclusions

The ablation success rate was much lower than those of earlier studies; the most plausible reason would be that higher risk DTC patients were included in this study. The low-dose RIT routinely performed in Japan might be inadequate for the achievement of successful ablation. At least for patients with Tg > 9 ng/mL at the first RIT, a higher dose of RAI is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–28.

    Article  CAS  Google Scholar 

  2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787–803.

    Article  CAS  Google Scholar 

  3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.

    Article  Google Scholar 

  4. Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: Is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055–61.

    Article  Google Scholar 

  5. Berney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33:645–9.

    Article  Google Scholar 

  6. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.

    Article  Google Scholar 

  7. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: A systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235–45.

    Article  CAS  Google Scholar 

  8. The Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery (JAES/JSTS) Task force on the guidelines for thyroid tumors. Japanese clinical practice guidelines for thyroid tumors. J JAES JSTS 2018; 35(Suppl 3):24–30 (In Japanese).

  9. Marti JL, Morris LGT, Ho AS. Selective use of radioactive iodine (RAI) in thyroid cancer: no longer "one size fits all". Eur J Surg Oncol. 2018;44:348–56.

    Article  CAS  Google Scholar 

  10. Matsuzu K, Sugino K, Masudo K, Nagahama M, Kitagawa W, Shibuya H, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1088 cases. World J Surg. 2014;38:68–79.

    Article  Google Scholar 

  11. Higashi T, Kudo T, Kinuya S. Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med. 2012;26:99–112.

    Article  CAS  Google Scholar 

  12. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 2012;22:310–7.

    Article  CAS  Google Scholar 

  13. Maruoka Y, Baba S, Isoda T, Kitamura Y, Abe K, Sasaki M, et al. A functional scoring system based on salivary gland scintigraphy for evaluating salivary gland dysfunction secondary to 131I therapy in patients with differentiated thyroid carcinoma. J Clin Diagn Res. 2017;11:TC23–TC28.

    PubMed  PubMed Central  Google Scholar 

  14. Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, et al. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative (131)I dose over 37 GBq. Clin Endocrinol (Oxf). 2015;83:117–23.

    Article  Google Scholar 

  15. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.

    Article  CAS  Google Scholar 

  16. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.

    Article  CAS  Google Scholar 

  17. Sabra MM, Grewal RK, Ghossein RA, Tuttle RM. Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. Thyroid. 2014;24:1088–95.

    Article  CAS  Google Scholar 

  18. Song X, Meng Z, Jia Q, Zhang L, Xu K, Tan J, et al. Different radioiodine dose for remnant thyroid ablation in patients with differentiated thyroid cancer. A meta-analysis. Clin Nucl Med. 2015;40:774–9.

    Article  Google Scholar 

  19. Higuchi T, Achmad A, Binh DD, Bhattarai A, Tsushima Y. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective. Endocr J. 2018;65:345–57.

    Article  CAS  Google Scholar 

  20. Jeong JH, Kong EJ, Jeong SY, Lee SW, Cho IH, Ah Chun K, et al. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer. Nucl Med Commun. 2017;38:228–33.

    Article  CAS  Google Scholar 

  21. Zhang Y, Wang C, Zhang X, Li H, Li X, Lin Y. 30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: A propensity score matching study. Endocrine. 2018;62:655–62.

    Article  CAS  Google Scholar 

  22. Iizuka Y, Katagiri T, Ogura K, Mizowaki T. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer. Ann Nucl Med. 2019;33:495–501.

    Article  CAS  Google Scholar 

  23. Wang C, Zhao T, Li H, Gao W, Lin Y. Low activity versus high activity: Noninferior response to radioiodine therapy in differentiated patients with extrathyroid extension. Nucl Med Commun. 2017;38:366–71.

    Article  CAS  Google Scholar 

  24. Shangguan L, Fang S, Zhang P, Han S, Shen X, Geng Y, et al. Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy. Ann Nucl Med. 2019;33:177–83.

    Article  CAS  Google Scholar 

  25. Fatima N, Zaman MU, Zaman A, Zaman U, Tahseen R. Comparable ablation efficiency of 30 and 100 mCi of I-131 for low to intermediate risk thyroid cancers using triple negative criteria. Asian Pac J Cancer Prev. 2016;17:1115–8.

    Article  Google Scholar 

  26. Ha S, Oh SW, Kim YK, Koo DH, Jung YH, Yi KH, et al. Clinical outcome of remnant thyroid ablation with low dose radioiodine in Korean patients with low to intermediate-risk thyroid cancer. J Korean Med Sci. 2015;30:876–81.

    Article  CAS  Google Scholar 

  27. Hussain SZ, Uz Zaman M, Malik S, Ram N, Asghar A, Rabbani U, et al. Preablation stimulated thyroglobulin/TSH ratio as a predictor of successful I131remnant ablation in patients with differentiated thyroid cancer following total thyroidectomy. J Thyroid Res. 2014;2014:610273. https://doi.org/10.1155/2014/610273.

    Article  CAS  Google Scholar 

  28. Prabhu M, Samson S, Reddy A, Venkataramanarao SH, Chandrasekhar NH, Pillai V, et al. Role of preablative stimulated thyroglobulin in prediction of nodal and distant metastasis on iodine whole-body scan. Indian J Nucl Med. 2018;33:93–8.

    Article  Google Scholar 

  29. Nixon AM, Provatopoulou X, Kalogera E, Zografos GN, Gounaris A. Circulating thyroid cancer biomarkers: Current limitations and future prospects. Clin Endocrin. 2017;87:117–26.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors declare that there are no conflicts of interest associated with this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Koichiro Abe.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abe, K., Ishizaki, U., Ono, T. et al. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer. Ann Nucl Med 34, 144–151 (2020). https://doi.org/10.1007/s12149-019-01432-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-019-01432-y

Keywords

Navigation